RELIGARE

- Religare Enterprises Ltd. (REL) subscribed to 4,21,05,264 equity shares of its wholly-owned subsidiary, Religare Broking Limited (RBL), for ₹100 Cr. to strengthen RBL's general business operations, scale up margin trade financing, and meet working capital needs.

- Q1 FY27 consolidated revenue grew 26% YoY to INR 2,358 Cr, but reported a negative consolidated PAT of INR 46.9 Cr and a negative PBT of INR 76.73 Cr (vs positive INR 5.73 Cr YoY). - RBI has not acceded to the company's demerger application, and management is engaging with the regulator to understand reasons and explore alternatives. The demerger deadline of Q1 FY28 is likely to be delayed. - Care Health Insurance: GWP grew 37% YoY, retail business grew 45% YoY, and PBT (Ind AS) increased to INR 163 Cr from INR 102 Cr YoY. Gross opex ratio improved by 100 bps to 31.2%, and combined ratio improved by 30 bps to 102.6%. The company raised INR 150 Cr through rights issue and INR 200 Cr via sub-debt, aiming to maintain a solvency ratio of 1.7x. Management intends to beat market growth. - Religare Broking: Total income increased 7% YoY to INR 99.5 Cr, with PBT growing 53% YoY to INR 10 Cr, driven by 13% growth in brokerage income. The company is focusing on strengthening its tech platform and product ecosystem for sustainable, profitable growth. - Religare Finvest: Net worth stands at INR 915 Cr with a healthy cash balance of INR 600 Cr. PAT for the quarter was INR 15 Cr (vs INR 17.9 Cr in Q1 FY26). NNPA is stable at 0.8% and CRAR at 238%. Management is rebuilding the business and aims for a INR 10,000-15,000 Cr book size with INR 1,500-2,000 Cr capital. - Religare Housing Finance: Reported a loss of INR 5 Cr for the quarter. The company has a net worth of INR 180 Cr with committed INR 250 Cr further capital and an AUM of INR 247 Cr. - Overall, INR 618 Cr proceeds have been received out of the planned INR 1,500 Cr capital raise, with INR 881 Cr due by March 2027.

- Audio recording of the earnings call held on August 13, 2026, to discuss Q1 FY27 operational & financial performance is now available on the company website.

- Q1 FY27 Consolidated Revenue ₹2,358.43 Cr vs ₹1,876.25 Cr (▲26% YoY) - EBITDA ₹(49.05) Cr vs ₹20.89 Cr (Swung to loss YoY) - PAT ₹(46.98) Cr vs ₹8.12 Cr (Swung to loss YoY) - EBITDA Margin -2.08% vs 1.11% (▼319 bps)

- Q1 FY27 Standalone Total Revenue from Operations ₹251.68 Lakhs vs ₹24.01 Lakhs (▲948.23% YoY) - PBT Loss ₹(961.97) Lakhs vs ₹(614.83) Lakhs (Loss widened by ▲56.46% YoY) - PAT Loss ₹(961.97) Lakhs vs ₹(614.83) Lakhs (Loss widened by ▲56.46% YoY) - EBITDA Loss ₹(1,075.17) Lakhs vs ₹(663.33) Lakhs (Loss widened by ▲62.09% YoY) - EBITDA Margin remained significantly negative at -427.29% vs -2762.72%. - The company is barred from declaring dividends as per an RBI letter issued in December 2019. - An ongoing governance review has been commissioned to identify potential instances of misconduct by current and/or ex-employees. - RBI has not acceded to the Scheme of Arrangement for demerger of financial services business into Religare Finvest Limited. - There are ongoing income tax litigations with a reduced demand of ₹10,853 Lakhs, which the company has appealed.

- Board of Directors approved Un-Audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The consolidated financial results table was not provided in this filing. - Standalone Q1 FY27: Total Income increased by 41.2% YoY to ₹438.17 Lakhs. However, Net Loss deepened to ₹961.97 Lakhs from ₹614.83 Lakhs in Q1 FY26. - Mr. Arjun Lamba re-designated as Managing Director, effective August 12, 2026, subject to shareholder approval. - Company is still barred from declaring dividends by RBI (since Dec 2019). - Significant unredeemed preference shares (₹41.9 Cr and ₹42.1 Cr) remain under legal dispute, involving a police complaint. - A governance review is commissioned to identify potential misconduct by current/ex-employees. RBI has not approved the demerger scheme. - Ongoing income tax litigation with a demand of ₹108.53 Cr (previously ₹139.96 Cr) is under appeal, with an interim stay granted.

- Q1 FY27 Standalone Revenue ₹251.68 Lakhs vs ₹24.01 Lakhs (▲948.23% YoY) - EBITDA (loss) ₹888.68 Lakhs vs ₹377.02 Lakhs (▼135.71% YoY, indicating larger loss) - PAT (loss) ₹961.97 Lakhs vs ₹614.83 Lakhs (▼56.46% YoY, indicating larger loss) - EBITDA Margin -353.19% vs -1570.26% (▲1217 bps, indicating less negative margin) - Mr. Arjun Lamba re-designated as Managing Director effective August 12, 2026. - Company is barred from declaring dividends as per RBI directives. - Multiple unredeemed preference shares are subject to ongoing litigations. - RBI has not acceded to the proposed demerger scheme with Religare Finvest Limited. - Significant income tax demand of ₹10,853 Lakhs is under appeal with an interim stay. - A governance review is in progress to identify potential misconduct and irregularities.

- Q1 FY27 Consolidated Revenue ₹2,353.40 Cr vs ₹1,871.52 Cr (▲25.74% YoY) - EBITDA (Loss) ₹(49.05) Cr vs EBITDA ₹20.89 Cr (Significant decline YoY) - PAT (Loss) ₹(46.98) Cr vs PAT ₹8.12 Cr (Significant decline YoY) - EBITDA Margin -2.08% vs 1.12% (▼320bps) - Board approved re-designation of Mr. Arjun Lamba as Managing Director. - Company is barred from declaring dividends by RBI since December 2019. - Ongoing disputes and sub-judice matters regarding unredeemed preference shares with Oscar Investments (₹41.90 Cr) and RHC Finance Pvt. Limited (₹42.13 Cr). - Governance review initiated to identify potential misconduct by current/ex-employees. - RBI has not acceded to the application for the Scheme of Arrangement for demerger. - Significant ongoing income tax litigation with a demand of ₹108.53 Cr (reduced from ₹139.96 Cr), appeal pending before ITAT. - IRDAI imposed a penalty of ₹1 Cr on subsidiary Care Health Insurance Ltd. (CHIL) and directed buyback of ESOP shares; matter is sub-judice.

- Religare Enterprises Limited has amended its "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information". - This amendment complies with Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. - The updated code is effective August 12, 2026, and is available on the company website.

- The Nomination and Remuneration Committee of Religare Enterprises Limited granted 13,195 Stock Options on August 12, 2026.- These options are under the Employee Stock Option Plan 2019, with an exercise price of ₹227.35 per equity share.- The options will vest in 5 equal annual installments of 20% each year.

- Concall Schedule - Concall Date: Thursday, 13th August 2026 - Concall Time: 04:00 PM IST

- RBI denied approval for the Scheme of Arrangement involving the transfer of Religare Enterprises Limited's undertaking to Religare Finvest Limited on August 6, 2026. - The companies will engage with the Regulator for further clarifications.

- RBI has not acceded to the application for the Scheme of Arrangement involving the transfer of Demerged Undertaking from Religare Enterprises Limited (REL) to Religare Finvest Limited (RFL). - REL and RFL will engage with the Regulator for further clarifications.

- Religare Enterprises Limited's material subsidiary, Care Health Insurance Limited (CHIL), allotted 20,000 debentures aggregating to ₹200 Crore at a coupon rate of 10.00% p.a. These were listed on the NSE Debt Segment on August 06, 2026.

New Filing detected. See link for details.

- IRDAI approved the voluntary surrender of the Insurance Web Aggregator Licence of MIC Insurance Web Aggregator Private Limited, a wholly-owned subsidiary, effective August 05, 2026. - MIC ceased to be an Insurance Web Aggregator. - The company stated there is no impact on the listed entity as MIC was not carrying on any business.

New Filing detected. See link for details.

- Mr. Anuj Jain, Company Secretary & Compliance Officer (KMP) of Religare Enterprises Limited, has resigned due to personal reasons. - His resignation is effective from the close of business hours on July 31, 2026.

- Religare Enterprises Ltd subscribed to 74,80,324 equity shares of its subsidiary Care Health Insurance Ltd. for ₹1,196.85 million via a rights issue on June 30, 2026. Funds will support CHIL's expansion and solvency.

New Filing detected. See link for details.

- Religare Enterprises Limited received 'no objection' from NSE and 'no adverse observations' from BSE on July 07, 2026, for its Scheme of Arrangement with Religare Finvest Limited. This allows the company to file the draft scheme with NCLT. The letters are valid for six months.

- Mr. Rahul Mehrotra has resigned as Managing Director (MD) & Chief Executive Officer (CEO) of Religare Housing Development Finance Corporation Limited (RHDFCL), a step-down subsidiary. - The resignation is effective from the close of business hours on June 30, 2026, upon completion of his current term.

- ICRA re-affirmed the credit rating for Religare Housing Development Finance Corporation Limited (RHDFCL) for Long-term/Short-term bank lines (₹400 Cr) at [ICRA]BBB- (Stable)/[ICRA]A3. The rating reflects adequate capitalization and group support, balanced by moderate operations and subdued profitability.

- The Trading Window for dealing in shares of Religare Enterprises Limited will close from July 01, 2026. - It will reopen 48 hours after the financial results for the quarter ended June 30, 2026, are declared. - The Board Meeting date to approve these results will be intimated in due course.

- Religare Housing Development Finance Corporation Limited (RHDFCL), a step-down subsidiary, has appointed Mr. Pavan Kumar Gupta as its Managing Director (MD) & Chief Executive Officer (CEO). - The appointment is effective from July 01, 2026, and is subject to shareholder approval. - Mr. Gupta has over 30 years of experience in building and transforming housing finance businesses.

- RBI has approved the appointment of Mr. Srinivasan Karthik as Director of Religare Finvest Limited (RFL) from June 23, 2026. - His appointment as Managing Director (in addition to his CEO role) becomes effective from June 23, 2026, subject to shareholder approval.